NCT05117424 CArdioMetabolism and Atherosclerotic PlaqUe progreSsion
| NCT ID | NCT05117424 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Ruijin Hospital |
| Condition | Coronary Artery Disease |
| Study Type | OBSERVATIONAL |
| Enrollment | 3,000 participants |
| Start Date | 2017-01-01 |
| Primary Completion | 2025-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 3,000 participants in total. It began in 2017-01-01 with a primary completion date of 2025-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Systematic metabolic diseases are closely related to prevalence and progression of atherosclerosis. This prospective cohort consecutively enrolls patients with coronary artery disease compliacted with metabolic abnormalities such as diabtetes, prediabetes, obesity, chronic kidney disease and hyperuricemia.
Eligibility Criteria
Inclusion Criteria: * Age 18-80 years * Established coronary artery disease or metabolic disorders, including: 1. Type 2 diabetes diagnosed by one of the following criteria: HbA1c \>/= 6.5% Fasting plasma glucose \>/= 7.0 mmol/l (confirmed) 2h plasma glucose value during OGTT \>/= 11.1 mmol/l Already receiving glucose-lowering agents 2. Prediabetes 3. Obesity 4. Chronic kidney disease 5. Hyperuricemia 6. Dyslipidemia Exclusion Criteria: * Severe liver failure (Child-Pugh grade B to C) * Severe anemia (hemoglobin \< 60g/L) * Familial hypercholesterolemia * Active malignant tumor * Active autoimmune diseases on corticosteroids * Acute or chronic infection * Life expectancy \< 1 year
Contact & Investigator
Lin Lu, M.D., Ph.D.
STUDY DIRECTOR
Ruijin Hospital, Shanghai Jiaotong School of Medicine
Frequently Asked Questions
Who can join the NCT05117424 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 80 Years, studying Coronary Artery Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05117424 currently recruiting?
Yes, NCT05117424 is actively recruiting participants. Contact the research team at xiaoqun_wang@hotmail.com for enrollment information.
Where is the NCT05117424 trial being conducted?
This trial is being conducted at Shanghai, China.
Who is sponsoring the NCT05117424 clinical trial?
NCT05117424 is sponsored by Ruijin Hospital. The principal investigator is Lin Lu, M.D., Ph.D. at Ruijin Hospital, Shanghai Jiaotong School of Medicine. The trial plans to enroll 3,000 participants.